Switching course, Gilead markets HIV drug for prevention
NEW YORK (Reuters) - Gilead Sciences Inc has begun marketing its HIV treatment Truvada in a way thousands of consumers already use it – to prevent infection with the virus that causes AIDS. (Source: Reuters: Health)
Source: Reuters: Health - November 30, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Tests to begin for HIV therapy injections, long-acting implants
Drugs from companies such as GlaxoSmithKline (NYSE:GSK), Gilead Sciences (NSDQ:GILD) and Merck (NYSE:MRK) are reportedly being considered for large-scale trials evaluating injectable HIV prevention therapies.
Eventually, researchers hope to produce matchstick-sized implants that could provide year-long protection to vulnerable populations.
Foster City, Calif.-based Gilead has a once-daily pill, Truvada, which prevents HIV infection during sex. Pre-exposure prophylaxis, also known as PrEP, can lessen the risk of catching the virus by more than 90% if the pill is taken regularly. Many patients, however, do not adhere to...
Source: Mass Device - November 29, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Implants Pharmaceuticals Research & Development Gilead Sciences GlaxoSmithKline plc Merck Source Type: news
Nurx raises $5.3M for app-based birth control and PrEP service
San Francisco-based Nurx, a telehealth company that offers prescriptions for birth control and HIV-prevention medication Truvada through an app, has raised $5.3 million in Series A funding in a round led by Union Square Ventures. Lowercase Capital, SV Angel and six Y Combinator partners also contributed. (Source: mobihealthnews)
Source: mobihealthnews - November 1, 2016 Category: Information Technology Source Type: news
Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil)
This new medicine evidence summary reviewed 4 randomised trials of Truvada (emtricitabine/tenofovir disoproxil 200 mg/245 mg) for pre-exposure prophylaxis (PrEP) of HIV in either HIV-negative men or transgender women who have sex with men, or HIV-negative individuals in a heterosexual partnership with a person already infected with HIV. In these trials, Truvada reduced the relative risk of acquiring HIV infection by between 44% and 86% compared with placebo or no prophylaxis, which is equivalent to approximate numbers needed to treat of between 13 and 68 per year. In all trials, Truvada was given in addition to a comprehen...
Source: Current Awareness Service for Health (CASH) - October 6, 2016 Category: Consumer Health News Source Type: news
European Commission Clears Truvada for HIV PrEP European Commission Clears Truvada for HIV PrEP
Truvada is indicated for PrEP in combination with safer sex practices to reduce the risk for sexually acquired HIV-1 infection in adults at high risk.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 23, 2016 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news
Gilead ’s Truvada for HIV-1 infection receives EC marketing approval
The European Commission (EC) has granted marketing authorisation for US-based Gilead Sciences ’ once-daily Truvada to reduce the risk of sexually acquired HIV-1 infection. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 22, 2016 Category: Pharmaceuticals Source Type: news
Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven
When investigators reviewed Emtricitabine/tenofovir alafenamide in HIV infection, they found that partly no data were available, and partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group, they conclude. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 18, 2016 Category: Science Source Type: news
Emtricitabine/tenofovir alafenamide in HIV infection: Added benefit not proven
(Institute for Quality and Efficiency in Health Care) Partly no data were available, partly the appropriate comparator therapy was not adhered to. The risk of nervous system disorders was increased for one patient group. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2016 Category: Global & Universal Source Type: news
UK Court Says State Health System Can Fund Preventative HIV Drug UK Court Says State Health System Can Fund Preventative HIV Drug
A high court judge ruled on Tuesday that pre-exposure prophylaxis (PrEP) against HIV using Gilead Sciences ' drug Truvada can be funded by the state health service in England, in a victory for AIDS campaigners who have been calling for its widespread use.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 3, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Truvada Recommended as First Drug for HIV PrEP in Europe Truvada Recommended as First Drug for HIV PrEP in Europe
Although not a new drug, it is the first drug for HIV preexposure prophylaxis to be recommended for approval in the European Union. < br / > < i > International Approvals < /i > (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 22, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
What’s keeping PrEP under wraps
PrEP, or pre-exposure prophylaxis, is a safe and effective medication that can prevent at-risk patients from contracting HIV, yet the treatment is not widely known by physicians or the patient base that could benefit most from it. Learn what HIV experts say about the treatment and the obstacles to integrating it into primary care practice.
Getting the word out
PrEP reaches a small proportion of the Americans who could benefit from it, experts said at an education session by the AMA LGBT Advisory Committee during the 2016 AMA Annual Meeting.
“What’s really interesting about it is a lot of people haven’t heard ab...
Source: AMA Wire - July 19, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news
What ’s keeping PrEP under wraps
< p >
PrEP, or pre-exposure prophylaxis, is a safe and effective medication that can prevent at-risk patients from contracting HIV, yet the treatment is not widely known by physicians or the patient base that could benefit most from it. Learn what HIV experts say about the treatment and the obstacles to integrating it into primary care practice. < /p > < p > < strong > Getting the word out < /strong > < /p > < p >
PrEP reaches a small proportion of the Americans who could benefit from it, experts said at an education session by the AMA LGBT Advisory Committee during the < a href= " http://www.ama-assn.org/sub/meeting/i...
Source: AMA Wire - July 19, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news
ViiV reports ARIA Phase IIIb trial shows superior efficacy for Triumeq to treat HIV
ViiV Healthcare reported that phase IIIb of the ARIA study showed superior efficacy for Triumeq (dolutegravir / abacavir / lamivudine) compared with atazanavir boosted with ritonavir (ATV/r), along with tenofovir disoproxil fumarate / emtricitabine (… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2016 Category: Pharmaceuticals Source Type: news
Anti-HIV Pill Could Cut Infections in Gay, Bi Men by a Third Anti-HIV Pill Could Cut Infections in Gay, Bi Men by a Third
The rate of new HIV infections among gay and bisexual men could drop by up to a third over the next decade if enough eligible men use pre-exposure prophylaxis (PrEP) with Truvada (emtricitabine/tenofovir disoproxil fumarate), researchers estimate. < br / > < i > Reuters Health Information < /i > (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 18, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Anti-HIV Pill Could Cut Infections in Gay, Bi Men by a ThirdAnti-HIV Pill Could Cut Infections in Gay, Bi Men by a Third
The rate of new HIV infections among gay and bisexual men could drop by up to a third over the next decade if enough eligible men use pre-exposure prophylaxis (PrEP) with Truvada (emtricitabine/tenofovir disoproxil fumarate), researchers estimate. Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 18, 2016 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
